Navigation Links
Is There Really Such a Thing as Hope in a Jar?
Date:11/13/2008

Dermatologists help consumers sort through the cosmeceutical conundrum

NEW YORK, Nov. 13 /PRNewswire/ -- When it comes to cosmeceuticals, consumers are bombarded by marketing claims that often fail to live up to their hype. Banking on promises that a product can "reverse the aging process" or "deliver the results of a facelift" leads consumers to spend billions of dollars each year to try an array of anti-aging skin care products. Their hope is that one day they will find a product that actually lives up to its claims.

Speaking today at the American Academy of Dermatology's SKIN academy (Academy), dermatologist Patricia K. Farris, MD, FAAD, clinical associate professor of dermatology at Tulane University School of Medicine in New Orleans, discussed how to separate fact from fiction when evaluating cosmeceuticals and tips for gauging the validity of product claims.

"When consulting with our patients, dermatologists can suggest skin care products that have strong science behind them and that have been proven to be safe and effective in human studies," said Dr. Farris. "The biggest problem with cosmeceuticals is not that they don't work, but that their benefits are greatly exaggerated."

Cosmeceuticals can be divided into categories based on their active ingredients. Anti-oxidants represent the largest category. They are followed by peptides (small proteins that stimulate the production of collagen and thicken the skin) and growth factors (compounds that act as chemical messengers between cells and play a role in cell division, new cell and blood vessel growth, and the production and distribution of collagen and elastin). More recently, Dr. Farris noted that the new trend is toward combination products. For example, cosmeceuticals with multiple anti-oxidants, retinol plus anti-oxidants, growth factors plus vitamin C and other unique combinations that are now being mass marketed. Consumers tend to favor combination products, embracing th
'/>"/>

SOURCE American Academy of Dermatology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
2. There's Still Time to Ensure Your Turkey Neck Doesn't Make an Appearance at Thanksgiving Dinner Thanks to Innovative Tuliplift
3. The Wireless World: Untethered Opportunities
4. MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource
5. Red Cross There as Hurricane Ike Roars Ashore
6. Asthma in boys may be just a phase, but for girls it may be there to stay
7. Pathway Medical Technologies Awarded New Patent for Pathway PV(TM) Atherectomy System for Improved Differential Cutting
8. AZO Answers the Burning Question: Whats Up Down There?
9. Let there be light
10. Experts Agree There is No Scientific Evidence of Health Risks in New Jersey Synthetic Turf Fields
11. Pelosi on Global HIV/AIDS Bill: There is a Moral Imperative to Combat This Epidemic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... “Today, we introduce our new items ... over the world. All these models are offered at ... the UK market,” says the CEO of the company. ... women’s special occasion outfits. , Ladies have to find ... is one of the best choices for many ladies ...
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides key ... provides value, in millions of US dollars, volume (in ... segments – Rigid Non-Video Sinuscopes. , The report also ... of these market categories, and global corporate-level profiles of ... deals related to the Sinuscopes market wherever available. , ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... to be filed in U.S. courts, Bernstein Liebhard LLP ... federal health regulators to ban uterine morcellation. According to ... a 46-year-old mother of four from California who was ... cancer called leiomyosarcoma just 10 days after undergoing a ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4
... of two titles, Journal of Analytical Toxicology ( JAT ... from Preston Publications, in a transaction managed by DeSilva+Phillips. The ... STM journal list published by OUP. "We are ... two titles. They have a rich history and we look forward ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- The ... a handy jet at your disposal, but the job also comes ... your life? Maybe not, new research suggests. The data showed ... years off their lives due to the effects of time spent ...
... HOBOKEN, NJ Keeping your brain in shapeno sweat. ... diet is just as important to maintaining mental performance ... are an easy, effective way to manage mental focus, ... antioxidant plant extract from the bark of the French ...
... depressive symptoms following birth also reported intimate partner violence finds ... An International Journal of Obstetrics and Gynaecology . The ... depressive symptoms first reported this at six months after birth ... emotional abuse) in the perinatal period is associated with a ...
... , TUESDAY, Dec. 6 (HealthDay News) -- New ... and when women with certain breast cancers will experience ... forms of breast cancer, are slated to be presented ... The research also revealed that genetic data gleaned ...
... in India are too poor to afford pacemakers. But a ... the devices and implanting them in Indian patients "is very ... Medical Center is a co-author of the study, published online ... . Kulkarni helped conduct the research before coming to Loyola ...
Cached Medicine News:Health News:Oxford University Press acquires 2 journals from Preston Publications 2Health News:Most U.S. Presidents Live Longer Than Their Peers 2Health News:Pycnogenol® found to improve memory and test scores in college students in new clinical trial 2Health News:Depressive symptoms and intimate partner violence in the 12 months after childbirth 2Health News:New Tests Might Better Predict Breast Cancer's Return 2Health News:New Tests Might Better Predict Breast Cancer's Return 3Health News:New Tests Might Better Predict Breast Cancer's Return 4Health News:Reusing pacemakers from deceased patients is safe and effective, study finds 2
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... SEATTLE, March 25 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... complete in,the phase III EXTEND (PIX301) clinical trial of ... non-Hodgkin,s lymphoma (NHL).,An analysis of the data is expected ... with the U.S. Food and Drug Administration (FDA) the ...
... Patients to ... Higher Rates of BARACLUDE Resistance -, PRINCETON, N.J., ... a continued low incidence of,resistance in nucleoside-naive patients through ... patients analyzed, no additional,patient developed resistance in the fifth ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 2Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: